BusinessSelecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe GoutBy Nasdaq OMXJun 15, 2017, 11:30 AM UTC
BusinessHorizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled GoutBy Nasdaq OMXJun 14, 2017, 1:05 PM UTC
